Clinical Trial Update: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating HLX10 and HLX04 alone or with HLX53 for untreated locally advanced or metastatic hepatocellular carcinoma; recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HLX04 (HLX04)
• HLX10
• HLX53

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: RECRUITING